Table of Contents

Component

t215 Bet v 1

t215 Bet v 1 Scientific Information

Type:

Component

Name; WHO/IUIS:

Bet v 1

Biological function:

Pathogenesis-related protein, ribonuclease

Allergen code:

t215

Route of Exposure:

Inhalation

Source Material:

Birch pollens – Silver Birch Tree allergen components

Other Names :

Major pollen allergen Bet v 1

Summary

Bet v 1 is a heat labile protein with a molecular weight of 17.5 kDa belonging to the PR-10 protein family. It is the major allergen of birch pollen. Up to 95% of birch pollen allergic patients have been reported to be sensitized to Bet v 1. Sensitization is prevalent in regions with birch pollen exposure, including Europe, North America and parts of Asia. In Europe, the lowest prevalence was observed in Portugal (6.8%) and the highest in Denmark (57.4%). Sensitization to Bet v 1 has been reported as a predictor of allergic rhinitis and asthma. There is extensive IgE cross-reactivity between Bet v 1 and pollen allergens from other Fagales trees such as hazel, beech, oak, and alder. The IgE cross-reactivity between Bet v 1 and homologous PR-10 proteins in plant foods such as fruits, vegetables and nuts is a key factor in the development of oral allergy syndrome (OAS).

Epidemiology

In Europe the prevalence of birch pollen sensitization ranges from approximately 8% to 16% in the general population (Biedermann 2019).

Regarding Bet v 1 sensitization in the European general population, a study of 501 adolescents in Austria found that 16.3% of participants had IgE-reactivity to Bet v 1 (Stemeseder 2017). Similarly, a German study of 17,641 children and adolescents reported that 14.1% were sensitized to Bet v 1 (Schmitz 2013).

Among European patients with tree-pollen allergy, a retrospective study of 854 patients with birch pollen sensitization in Italy, reported that sensitization to Bet v 1 ranged from 53% to 95%, depending on the region (Ciprandi 2016). In a study of 260 patients with tree pollen allergy in Germany, 239 (92%) patients were sensitized to Bet v 1 (Canis 2011). Of these 239 patients, all (100%) also showed IgE-reactivity to hazel and alder pollen extract.

A study from Japan detected specific IgE towards Bet v 1 in 39 (97,5%) out of 40 patients' sera with specific IgE towards birch pollen extract (Shirasaki 2008) and in a study from Korea involving 31 children with specific IgE to birch pollen, 24 children (77%) were sensitized to Bet v 1 (Baek, 2020). Among the Korean children, 13 had oral allergy syndrome (OAS), and all of them (100%) were Bet v 1 sensitized. Bet v 1 sensitization was detected in 11 (61%) out of 18 children without OAS (Baek 2020).

A study from Beijing, China involving 58 birch pollen allergic patients detected Bet v 1 sensitization in 48 (82.8%) patients (Wang 2023). Similarly, in a study conducted in northern China, 203 patients with allergic rhinitis or asthma were tested for specific IgE against birch pollen extract and Bet v 1. Among the 203 patients, 16.7% (n=34) had specific IgE to birch pollen extract, and of those, 82.4% (n=28) had specific IgE to Bet v 1 (Hao 2016). This study also found that most patients sensitized to Bet v 1 showed IgE-reactivity to the apple allergen Mal d 1 and the soybean allergen Gly m 4, potentially leading to manifestations of oral allergy syndrome (Hao 2016).

The prevalence of birch pollen sensitization in the United States is reported to be approximately 7% among individuals aged 6 years and older (Salo 2014). However, there is a paucity of published data regarding the prevalence of Bet v 1 sensitization in North America.

Environmental Characteristics

Source and tissue

Bet v 1 is located in the cytoplasm of the pollen grain (Grote 1999) with an estimated concentration of 0.004 ng of Bet v 1 per pollen grain, which represents 13.9% of the soluble protein (Schäppi1997). Recombinant Bet v 1 is routinely produced for research and in vitro IgE testing purpose.

Risk factors

Climate change may impact the incidence and prevalence of pollen allergies due to increased exposure to allergenic pollens through geographic spread, longer pollen seasons with higher pollen counts, and enhanced pollen allergenicity (Burbank 2025).

Clinical Relevance

Bet v 1 is a primary sensitizer in birch pollen-endemic regions, leading to allergic reactions such as allergic rhinoconjunctivitis with typical symptoms sneezing, runny or blocked nose, itchy and watery eyes, and general nasal congestion (Caillaud 2014). In Bet v 1 sensitized individuals, exposure to birch pollen can lead to asthmatic symptoms, including wheezing, shortness of breath, chest tightness, and coughing (Canova 2013).

Sensitization to Bet v 1 can lead to IgE-mediated cross-reactivity to homologous allergens present in various fruits, vegetables, and nuts, potentially causing oral allergy syndrome (OAS) (Al-Shaikhly 2024). Symptoms of OAS typically include itching, tingling, and swelling in the mouth and throat (Muluk 2018). A study from Korea found that 20% (n=25) of birch pollen sensitized patients developed OAS. Among these patients suffering from OAS, symptoms included rhino-conjunctivitis (75%), asthma (20%), and chronic urticaria (12%) (Kim 2018). Although rare, some individuals may experience more severe systemic reactions (Kleine-Tebbe 2002).

Diagnostic Relevance

Bet v 1 has been recommended as a marker allergen to identify patients with genuine sensitization to birch pollen and Bet v 1 sensitization is considered important for the selection of patients suitable for birch pollen AIT (Dramburg 2023). Studies on cross-reactivity have shown that patients with specific IgE to Bet v 1 are also IgE-reactive to Bet v 1 homologous allergens from the order Fagales (hazel, alder, hornbeam, oak), and from certain plant-based foods indicative of OAS manifestations. Specific IgE cut-off levels in kU_A/L have been proposed for identifying OAS patients but these varies between populations and region.

Prevention and Therapy

Bet v 1 sensitization is considered important for the selection of patients suitable for birch pollen allergen specific immunotherapy (AIT) (Dramburg 2023).

Experimental AIT trials

In a 2-year randomized placebo-controlled trial involving 134 subjects, subcutaneous AIT using recombinant Bet v 1 demonstrated similar efficacy to conventional birch pollen extract AIT and AIT with Bet v 1 purified from pollen in reducing rhino-conjunctivitis symptoms and the use of rescue medication (Pauli 2008).

Subcutaneous AIT with a hypoallergenic recombinant Bet v 1 variant was compared to conventional birch pollen extract AIT in a recent 6-month trial involving 47 subjects (Aglas 2025). Despite skin prick test (SPT) confirmation of hypo-allergenicity (approximately 50% compared to natural Bet v 1), more adverse events were reported in response to the hypoallergenic Bet v 1 AIT than with the conventional extract AIT (Aglas 2025).

In a sublingual AIT multicentre, placebo-controlled study conducted in 483 patients with birch pollen-induced rhinoconjunctivitis, recombinant Bet v 1 AIT showed efficacy results consistent with what is observed following sublingual AIT with birch pollen extract (Noy 2015).

Molecular Aspects

Bet v 1 is a protein of the pathogenesis‐related class 10 (PR‐10) family with a molecular weight of 17.5 kDa (Ipsen 1983, Breiteneder 1989). The WHO/IUIS Allergen Nomenclature Sub-Committee database lists nearly 30 isoforms of Bet v 1, all of which have been shown to be expressed in pollen at least at the mRNA level. The amino acid identity between these isoforms ranges from 70% to 95%. The clinical relevance of this large number of isoforms remains uncertain.

Bet v 1 is heat labile protein and rapidly denatured by cooking (Vieths 2002).

As for other members of the PR-10 protein family, Bet v 1 tertiary structure forms a hydrophobic pocket that may accommodate various small molecules, such as plant hormones, flavonoids, fatty acids or other small hydrophobic molecules (Mogensen 2002, Marković-Housley 2003). The binding of these ligands is thought to be important for the role of Bet v 1 in plant defence and stress response (Aglas 2020).

Cross-reactivity

There is a high degree of amino acid sequence identity between Bet v 1 and its homologous allergens in Fagales pollen, with Car b 1 (hornbeam), Aln g 1 (alder), and Cor a 1 (hazel) showing 79% to 83% identity. Que a 1 (oak) has a 58% amino acid sequence identity with Bet v 1. The major allergens of chestnut (Cas s 1) and beech (Fag s 1) display 75% and 69% (N-terminal) amino acid sequence homology with Bet v 1, respectively (Biedermann, 2019). This high degree of sequence identity leads to similar tertiary structures, and the molecular structure of Bet v 1 has revealed conformational epitopes involved in IgE cross-reactivity (Gajhede, 1996; Spangfort 2003).

Similarly, the amino acid sequence similarities between Bet v 1 and PR-10 proteins in certain fruits, nuts, and vegetables can be high, such as approximately 60% between Bet v 1 and the apple allergen Mal d 1 (Holm 2001). This leads to similar three-dimensional structures and potential IgE cross-reactivity. The extent of cross-reactivity in an individual patient is determined by the degree of sequence and structural similarities, as well as the epitope repertoire of Bet v 1 IgE antibodies.

Foods containing Bet v 1 homologous PR-10 protein includes apple, pear, cherry, peach, nectarine, apricot, plum, kiwi, carrot, celery, hazelnut, almond, walnut and soybean (Kato 2025).

Exposure

The main exposure route for Bet v 1 is through inhalation (airway) of birch pollen as Bet v 1 is released from pollen on the mucosa.

Exposure to Bet v 1 homologous PR-10 proteins can occur via ingestion of certain fruits, vegetables and nuts causing symptoms of oral allergy syndrome (OAS).

Explained Results

Allergen information

Bet v 1 belongs to the PR-10 protein family and is the major allergen of birch pollen. Sensitization to Bet v 1 has been reported in up to 95% of individuals allergic to birch pollen. Bet v 1 is heat labile allergen. There are nearly 30 isoforms of Bet v 1 described. Bet v 1 homologous PR-10 proteins are found in other Fagales tree pollens, as well as in various fruits, nuts and vegetables.

Clinical relevance

Bet v 1 is a primary sensitizer in birch pollen-endemic regions, leading to allergic rhinitis and sometimes asthma. Sensitization to Bet v 1 can lead to food oral allergy syndrome (OAS).

Cross-reactivity

There is extensive IgE cross-reactivity between Bet v 1 and pollen allergens from other Fagales trees such as hazel, beech, oak, and alder, and to homologous allergenic PR-10 proteins in plant foods such as fruits, vegetables and nuts.

Compiled By

Author: Turacoz Healthcare Solutions

Reviewer: Dr. Magnus Borres

Last Reviewed by Dr. Michael Spangfort, September 2025.

References

Aglas L, Soh WT, Kraiem A, Wenger M, Brandstetter H, Ferreira F. Ligand Binding of PR-10 Proteins with a Particular Focus on the Bet v 1 Allergen Family. Curr Allergy Asthma Rep. 2020;20(7):25.

Aglas L, Tannert LK, Versteeg SA, Smith SA, Bartko EA, Wenger M, Kraiem A, Widauer H, Nunes N, Sinkunaite S, Stolz F, Jongejan L, Neubauer A, Blom LH, Ferreira F, Poulsen LK, Bindslev-Jensen C, van Ree R. Subcutaneous Allergen Immunotherapy With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG₁ Instead of IgG₄. Allergy. 2025; 80(7):2018-2030.

Al-Shaikhly T, Cox A, Nowak-Wegrzyn A, Cianferoni A, Katelaris C, Ebo DG, Konstantinou GN, Brucker H, Yang HJ, Protudjer JLP, Boechat JL, Yu JE, Wang J, Hsu Blatman KS, Blazowski L, Anand MP, Ramesh M, Torres MJ, Holbreich M, Goodman R, Wasserman RL, Hopp R, Sato S, Skypala I. An International Delphi Consensus on the Management of Pollen-Food Allergy Syndrome: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee. J Allergy Clin Immunol Pract. 2024;12(12):3242-3249.

Baek HS, Jeong JW, Lee HB, Kwon JW. Molecular sensitization patterns in birch pollen-sensitized Korean children according to the presence of oral allergy syndrome. Medicine (Baltimore). 2020;99(10):e19469.

Biedermann T, Winther L, Till S, Panzner P, Knulst A, Valovirta E. Birch pollen allergy in Europe. Allergy. 2019;74(7):1237-1248.

Burbank AJ. Climate Change and the Future of Allergies and Asthma. Curr Allergy Asthma Rep. 2025 Mar 27;25(1):20.

Breiteneder H, Pettenburger K, Bito A, Valenta R, Kraft D, Rumpold H, Scheiner O, Breitenbach M. The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J. 1989;8(7):1935-1938.

Caillaud D, Martin S, Segala C, Besancenot JP, Clot B, Thibaudon M; French Aerobiology Network. Effects of airborne birch pollen levels on clinical symptoms of seasonal allergic rhinoconjunctivitis. Int Arch Allergy Immunol. 2014;163(1):43-50.

Canova C, Heinrich J, Anto JM, Leynaert B, Smith M, Kuenzli N, Zock JP, Janson C, Cerveri I, de Marco R, Toren K, Gislason T, Nowak D, Pin I, Wjst M, Manfreda J, Svanes C, Crane J, Abramson M, Burr M, Burney P, Jarvis D. The influence of sensitisation to pollens and moulds on seasonal variations in asthma attacks. Eur Respir J. 2013;42(4):935-945.

Ciprandi G, Comite P, Mussap M, De Amici M, Quaglini S, Barocci F, et al. Profiles of birch sensitization (Bet v 1, Bet v 2, and Bet v 4) and oral allergy syndrome across Italy. J Investig Allergol Clin Immunol. 2016;26(4):244-248.

Dramburg S, Hilger C, Santos AF, de Las Vecillas L, Aalberse RC, Acevedo N, Aglas L, Altmann F, Arruda KL, Asero R, Ballmer-Weber B, Barber D, Beyer K, Biedermann T, Bilo MB, Blank S, Bosshard PP, Breiteneder H, Brough HA, Bublin M, Campbell D, Caraballo L, Caubet JC, Celi G, Chapman MD, Chruszcz M, Custovic A, Czolk R, Davies J, Douladiris N, Eberlein B, Ebisawa M, Ehlers A, Eigenmann P, Gadermaier G, Giovannini M, Gomez F, Grohman R, Guillet C, Hafner C, Hamilton RG, Hauser M, Hawranek T, Hoffmann HJ, Holzhauser T, Iizuka T, Jacquet A, Jakob T, Janssen-Weets B, Jappe U, Jutel M, Kalic T, Kamath S, Kespohl S, Kleine-Tebbe J, Knol E, Knulst A, Konradsen JR, Korošec P, Kuehn A, Lack G, Le TM, Lopata A, Luengo O, Mäkelä M, Marra AM, Mills C, Morisset M, Muraro A, Nowak-Wegrzyn A, Nugraha R, Ollert M, Palosuo K, Pastorello EA, Patil SU, Platts-Mills T, Pomés A, Poncet P, Potapova E, Poulsen LK, Radauer C, Radulovic S, Raulf M, Rougé P, Sastre J, Sato S, Scala E, Schmid JM, Schmid-Grendelmeier P, Schrama D, Sénéchal H, Traidl-Hoffmann C, Valverde-Monge M, van Hage M, van Ree R, Verhoeckx K, Vieths S, Wickman M, Zakzuk J, Matricardi PM, Hoffmann-Sommergruber K. EAACI Molecular Allergology User's Guide 2.0. Pediatr Allergy Immunol. 2023;34 Suppl 28:e13854.

Gajhede M, Osmark P, Poulsen FM, Ipsen H, Larsen JN, Joost van Neerven RJ, Schou C, Løwenstein H, Spangfort MD. X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nat Struct Biol. 1996;3(12):1040-1045.

Grote M. In situ localization of pollen allergens by immunogold electron microscopy: allergens at unexpected sites. Int Arch Allergy Immunol. 1999;118(1):1-6.

Hao G-d, Zheng Y-w, Wang Z-x, Kong X-a, Song Z-j, Lai X-x, et al. High correlation of specific IgE sensitization between birch pollen, soy and apple allergens indicates pollen-food allergy syndrome among birch pollen allergic patients in northern China. Journal of Zhejiang University-SCIENCE B. 2016;17(5):399-404.

Holm J, Baerentzen G, Gajhede M, Ipsen H, Larsen JN, Løwenstein H, Wissenbach M, Spangfort MD. Molecular basis of allergic cross-reactivity between group 1 major allergens from birch and apple. J Chromatogr B Biomed Sci Appl. 2001;756(1-2):307-313.

Ipsen H, Løwenstein H. Isolation and immunochemical characterization of the major allergen of birch pollen (Betula verrucosa). J Allergy Clin Immunol. 1983;72(2):150-159.

Kato Y, Morikawa T, Fujieda S. Comprehensive review of pollen-food allergy syndrome: Pathogenesis, epidemiology, and treatment approaches. Allergol Int. 2025;74(1):42-50.

Kim JH, Kim SH, Park HW, Cho SH, Chang YS. Oral Allergy Syndrome in Birch Pollen-Sensitized Patients from a Korean University Hospital. J Korean Med Sci. 2018; 3;33(33):e218

Kleine-Tebbe J, Vogel L, Crowell DN, Haustein UF, Vieths S. Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1- related PR-10 protein in soybean, SAM22. J Allergy Clin Immunol. 2002;110(5):797-804.

Marković-Housley Z, Degano M, Lamba D, von Roepenack-Lahaye E, Clemens S, Susani M, Ferreira F, Scheiner O, Breiteneder H. Crystal structure of a hypoallergenic isoform of the major birch pollen allergen Bet v 1 and its likely biological function as a plant steroid carrier. J Mol Biol. 2003;325(1):123-133.

Mogensen JE, Wimmer R, Larsen JN, Spangfort MD, Otzen DE. The major birch allergen, Bet v 1, shows affinity for a broad spectrum of physiological ligands. J Biol Chem. 2002;277(26):23684-92.

Muluk NB, Cingi C. Oral allergy syndrome. Am J Rhinol Allergy. 2018;32(1):27-30.

Nony E, Bouley J, Le Mignon M, Lemoine P, Jain K, Horiot S, et al. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients. Allergy. 2015;70(7):795-804.

Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122(5):951-960.

Salo PM, Arbes SJ Jr, Jaramillo R, Calatroni A, Weir CH, Sever ML, Hoppin JA, Rose KM, Liu AH, Gergen PJ, Mitchell HE, Zeldin DC. Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005-2006. J Allergy Clin Immunol. 2014;134(2):350-359.

Schmitz R, Ellert U, Kalcklösch M, Dahm S, Thamm M. Patterns of sensitization to inhalant and food allergens - findings from the German Health Interview and Examination Survey for Children and Adolescents. Int Arch Allergy Immunol. 2013;162(3):263-270.

Schäppi GF, Suphioglu C, Taylor PE, Knox RB. Concentrations of the major birch tree pollen allergen Bet v 1 in pollen and respirable fine particles in the atmosphere. J Allergy Clin Immunol. 1997; 100:656-661.

Shirasaki H, Yamamoto T, Koyanagi Y, Watanabe N, Himi T. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4. Allergol Int. 2008;57(1):93-96.

Spangfort MD, Mirza O, Ipsen H, Van Neerven RJ, Gajhede M, Larsen JN. Dominating IgE-binding epitope of Bet v 1, the major allergen of birch pollen, characterized by X-ray crystallography and site-directed mutagenesis. J Immunol. 2003;171(6):3084-3090.

Stemeseder T, Klinglmayr E, Moser S, Lueftenegger L, Lang R, Himly M, et al. Cross‐sectional study on allergic sensitization of Austrian adolescents using molecule‐based IgE profiling. Allergy. 2017;72(5):754-763.

Vieths S, Scheurer S, Ballmer-Weber B. Current understanding of cross-reactivity of food allergens and pollen. Ann N Y Acad Sci. 2002; 964:47-68.

Wang X, Chen L, Ding J, Wang H, Wang X. Profiles of Birch Allergen Component Sensitization and Its Association with Pollen Food Allergy Syndrome in Northern China. J Asthma Allergy. 2023; 16:1241-1250.